Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ACP3 | P15309 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7782825 | 0.97 | HTR2A (0.54) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| Bromide SCHEMBL9538904 | 0.86 | SNCA (0.46) | HTR2AHTR2BHTR2CSNCA | |
| Iodide SCHEMBL16398702 | 0.83 | TACR1 (0.45) | HTR2AHTR2BHTR2CSNCA | |
| Bromide SCHEMBL6524406 | 0.82 | SNCA (0.55) | TAAR1SIGMAR1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL1840962 | 0.81 | SNCA (0.56) | ACP3TAAR1TSHRMAPTIDO1 | |
| Bromide SCHEMBL29255353 | 0.80 | HTR2A (0.62) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| Hydrochloric Acid SCHEMBL5149449 | 0.78 | SNCA (0.52) | TAAR1SIGMAR1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL1352977 | 0.77 | SNCA (0.47) | TAAR1IDO1PPARGPPARAMEN1 | |
| Hydrochloric Acid SCHEMBL9419870 | 0.77 | SNCA (0.53) | ACP3TAAR1TSHRMAPTIDO1 | |
| Bromide SCHEMBL163158 | 0.75 | SNCA (0.67) | TAAR1SIGMAR1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| CN-114249718-B | Sulfonium salt derivative, preparation method and medical application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-3426634-A1 | DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | University of Ljubljana (SI) | 2019-01-16 | — | — | EP | disclosed |
| WO-2018055096-A1 | DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF LJUBLJANA (SI) | 2018-03-29 | — | — | WO | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| EP-0818197-B1 | Heterocyclic condensed pyridines as CETP inhibitors | BAYER AG (DE) | 2003-11-12 | — | — | EP | disclosed |
| EP-0968162-A1 | 5-HYDROXYALKYL SUBSTITUTED PHENYLS AND THEIR USE IN MEDICAMENTS FOR THE TREATMENT OF ARTERIOSCLEROSIS AND HYPERLIPOPROTEINAEMIA | BAYER AG (DE) | 2000-01-05 | — | — | EP | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5932587-A | FOR TREATMENT OF DISLIPIDAEMIA, ARTERIOSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| US-5925645-A | ARTERIOSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-20 | — | — | US | disclosed |
| WO-1998034895-A1 | 5-HYDROXYALKYL SUBSTITUTED PHENYLS AND THEIR USE IN MEDICAMENTS FOR THE TREATMENT OF ARTERIOSCLEROSIS AND HYPERLIPOPROTEINAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-13 | — | — | WO | disclosed |
| EP-0825185-A1 | Pyridine fused to a bicyclic ring | BAYER AG (DE) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0818197-A1 | Heterocyclic condensed pyridines as CETP inhibitors | BAYER AG (DE) | 1998-01-14 | — | — | EP | disclosed |
| EP-0796846-A1 | 2-Aryl substituted pyridines | BAYER AG (DE) | 1997-09-24 | — | — | EP | disclosed |
| US-5266593-A | Substituted pyran derivatives having antiinfective activity | E. R. SQUIBB & SONS, INC. (US) | 1993-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | HTR2A 324/4885HTR2B 357/4885HTR2C 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.